Market Overview

J.P. Morgan Reiterates Neutral Rating on Humana

Share:
Related HUM
Citi Concerned With Near-Term Risks For Cotiviti, Initiates At Neutral
12 Stocks You Should Be Watching Today
Bloomberg: Aetna plans to sell assets to address anti-trust concerns (Seeking Alpha)

In a report published Monday, J.P. Morgan reiterated its Neutral rating on Humana (NYSE: HUM).

J.P. Morgan noted, “Q4 adjusted EPS of $1.19 beats JPMe/consensus $1.05/$1.07 and guidance of $0.98-$1.08 primarily on lower SG&A ($0.11 benefit) and tax rate ($0.08) and with MLR 10 bps above our model on $25m or $0.10 of flu costs and $0.05 of transaction costs. Revenue was $9.56B, slightly below JPMe/consensus of $9.68B/$9.75B. 2013 EPS guidance unchanged despite inclusion of MDF acquisition $0.06, as offset by $0.20 of Q1 flu now baked into #'s. Although retail MLR guidance is up 50 bps (~$0.50 of EPS based on midpoint of rev guidance), the operating earnings guidance for the segment (and also the consolidated SG&A outlook) are unchanged. Open enrollment results in line with expectations, and Med Adv guidance for 2013 reiterated.”

Humana closed on Friday at $75.35.

Latest Ratings for HUM

DateFirmActionFromTo
Dec 2015Credit SuisseInitiates Coverage onNeutral
Sep 2015JP MorganInitiates Coverage onOverweight
Sep 2015RBC CapitalMaintainsSector Perform

View More Analyst Ratings for HUM
View the Latest Analyst Ratings

Posted-In: J.P. MorganAnalyst Color Reiteration Analyst Ratings

 

Related Articles (HUM)

View Comments and Join the Discussion!